Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:APHANASDAQ:APMNASDAQ:SPK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$20.42+1.3%$20.64$9.35▼$25.67$4.87B0.573.70 million shs1.32 million shsAPHAAphria$15.38$15.48$2.78▼$32.29$4.87B2.6721.83 million shsN/AAPMAptorum Group$0.89+3.2%$0.89$0.46▼$7.49$4.75M-0.16613,360 shs8,274 shsSPKSPK Acquisition$10.30$10.22$9.84▼$10.68$67.94M-0.0112,839 shs33,515 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.20%+5.00%-5.75%+27.27%+109.35%APHAAphria0.00%0.00%0.00%0.00%0.00%APMAptorum Group-4.58%-12.22%-5.78%-21.45%-78.76%SPKSPK Acquisition0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics3.175 of 5 stars2.64.00.00.04.21.71.9APHAAphriaN/AN/AN/AN/AN/AN/AN/AN/AAPMAptorum Group0.3572 of 5 stars0.03.00.00.00.01.70.6SPKSPK AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2518.76% UpsideAPHAAphria 0.00N/AN/AN/AAPMAptorum Group 0.00N/AN/AN/ASPKSPK Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APM, SPK, APHA, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.003/4/2025ADMAADMA BiologicsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.61$0.07 per share311.70$0.60 per share34.03APHAAphria$405.96M12.00$0.09 per share166.43$4.80 per share3.20APMAptorum Group$430K11.04N/AN/A$2.97 per share0.30SPKSPK AcquisitionN/AN/AN/AN/A($0.19) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8572.9329.59N/A17.80%53.20%26.07%N/AAPHAAphria-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/AAPMAptorum Group-$2.83MN/A0.00∞N/AN/AN/AN/AN/ASPKSPK Acquisition-$420KN/A0.00∞N/AN/AN/A-1.95%N/ALatest APM, SPK, APHA, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAPHAAphriaN/AN/AN/AN/AN/AAPMAptorum GroupN/AN/AN/AN/AN/ASPKSPK AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26APHAAphria0.252.361.17APMAptorum Group0.241.16N/ASPKSPK AcquisitionN/A4.644.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%APHAAphria10.30%APMAptorum Group3.80%SPKSPK Acquisition19.64%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%APHAAphriaN/AAPMAptorum Group63.99%SPKSPK Acquisition22.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableAPHAAphria1,200316.80 millionN/AOptionableAPMAptorum Group305.35 million1.87 millionNot OptionableSPKSPK Acquisition2,0216.60 million5.12 millionNot OptionableAPM, SPK, APHA, and ADMA HeadlinesRecent News About These CompaniesASX 200 telco marches higher on $820 million asset saleJuly 11, 2022 | fool.com.auP&W, Embraer complete first full-SAF test flight with E195-E2July 2, 2022 | flightglobal.comPiezoelectric Tiles Market Research Report by Material, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19June 27, 2022 | uk.finance.yahoo.comSPK Acquisition Corp. Cl AMay 21, 2022 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPM, SPK, APHA, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$20.42 +0.26 (+1.29%) Closing price 04:00 PM EasternExtended Trading$20.42 +0.00 (+0.02%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Aphria NASDAQ:APHAAphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Aptorum Group NASDAQ:APM$0.89 +0.03 (+3.22%) Closing price 03:48 PM EasternExtended Trading$0.86 -0.03 (-3.37%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.SPK Acquisition NASDAQ:SPKSPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
